Skip to content

Washington, D.C. · Nonprofit

DRUG INFORMATION ASSOCIATION INC

DRUG INFORMATION ASSOCIATION INC (Washington, D.C.) receives grants from 2 organizations whose IRS filings report $26,335 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($20,335). 0 of them have funded it in more than one year.

Revenue FY2025
$18M
Funders on record
2
Grants received
$26k
Net assets
$3.4M
0/2 repeat funderspeak grant-dependency 0%
01What it does

What Drug Information Association Inc does

Mission

Drug information association, inc. ("dia") fosters innovation to improve health and wellbeing worldwide by: - providing invaluable forums to exchange vital information and discuss current issues related to health products, technologies, and services; - delivering customized learning experiences;- building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share dia values and mandates; and - offering a multidisciplinary neutral environment, respected globally for integrity and relevancy.

As stated on its FY2025 Form 990.

Programs

  1. In 2025 dia held more than 288 meetings and workshops worldwide, dia attracted over 26k+ participants to meetings and workshops in the united states, europe, china, japan and india.among these events, the dia global annual meeting, the leading global conference on pharmaceutical information and education, attracted over 3,500 participants from the us and across the world. The dia european annual meeting, which is recognized as one of the premier forums for the exchange of information in the european medical/pharmaceutical community, attracted 1,106 participants. The japan annual meeting, singapore annual meeting and china annual meeting had 649, 138 and 7,458 participants, respectively.

    $10,686,463 spent$12,225,310 earned by the program
    69% of program spending
  2. Learning: with an on-going commitment to internet technology-based learning, dia continued to expand its global reach and advance its mission by offering various learning opportunities in electronic format. In 2025, dia had 1,530 e-learners including both individuals and groups. In addition, there were 52 training courses held globally with 2,022 participants trained through these training courses.

    $2,134,369 spent$2,441,717 earned by the program
    14% of program spending
  3. Dia membership: dia provides programs to develop, strengthen, and support collaboration with policy makers, industry representatives, public health authorities, academia and other healthcare stakeholders.

    $1,101,623 spent$1,260,256 earned by the program
    7% of program spending
  4. Publications: therapeutic innovation & regulatory science publication (tirs) is the official journal of dia. Its mission is to advance healthcare product discovery, development, regulation, and use through the publication of peer-reviewed articles and commentaries across the spectrum of converting biomedical science into practical solutions to advance human health. It is published in odd number months, january, march, may, july, september, and november. Dia also publishes the global forum, another e-publication. It offers expert global and regional coverage of discovery, development, regulation, surveillance, and marketing of healthcare products, including interviews with leaders and topical summaries from educational events. It is published monthly.

    $323,203 spent$369,744 earned by the program
    2% of program spending
  5. Collaborative studies

    $1,202,294 spent$1,375,424 earned by the program
    8% of program spending

The 5 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $15,447,952.

02The organization over time

The organization over time

Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

100 = 20172017 Revenue 100 ($23M) Expenses 100 ($23M) Net assets 100 ($6.6M)2018 Revenue 104 ($24M) Expenses 102 ($23M) Net assets 89 ($5.9M)2019 Revenue 107 ($24M) Expenses 104 ($24M) Net assets 108 ($7.1M)2020 Revenue 83 ($19M) Expenses 82 ($19M) Net assets 119 ($7.9M)2021 Revenue 84 ($19M) Expenses 75 ($17M) Net assets 149 ($9.9M)2022 Revenue 88 ($20M) Expenses 97 ($22M) Net assets 106 ($7.0M)2023 Revenue 97 ($22M) Expenses 100 ($23M) Net assets 104 ($6.9M)2024 Revenue 88 ($20M) Expenses 96 ($22M) Net assets 80 ($5.3M)2025 Revenue 80 ($18M) Expenses 90 ($21M) Net assets 52 ($3.4M)
'17'18'19'20'21'22'23'24'25
Revenue (80)Expenses (90)Net assets (52)Peer revenue range

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2021 to 2022, from $19M to $24M (+28%).

$17M
$15M
$16M
$20M
$19M
$24M
$24M
$23M
$23M
'17'18'19'20'21'22'23'24'25
Total assetsTotal liabilities

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

2017
2018
2019
2020
2021
2022
2023
2024
2025
ContributionsProgram revenueInvestmentOther

Government-grant reliance: 2021 11%. Grants only. Government contracts and fees sit inside program revenue.

0% of DRUG INFORMATION ASSOCIATION INC’s revenue is contributions — more earned-revenue than three-quarters of its peers (7% for the typical peer).

This organization
Typical peer · 4,745 orgs

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 6 of the last 9 reported years ran a deficit.

−$430k
’17
$157k
’18
$127k
’19
−$117k
’20
$1.6M
’21
−$2.5M
’22
−$1.1M
’23
−$2.1M
’24
−$2.6M
’25
0.6
months of
reserve

Leadership and staff

The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.

Chief executive

Marwan Fathallah

President & chief executive officer

Board chair

Junaid Bajwa

Chair

As listed on its FY2025 Form 990.

The chief executive listed changed between the FY2018 and FY2019 filings.

'17'18'19'20'21'22'23'24'25
Listed332630242725312929
Joined·+8+12+4+5+7+10+6+6
No longer listed·1581029486
03Who funds it

Who funds it, year by year

Grant support over time, funder by funder — shade shows the grant size each year.

From the IRS filings of DRUG INFORMATION ASSOCIATION INC’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

DRUG INFORMATION ASSOCIATION INC leans on a few funders — its largest provides 77% of grant income and the top three 100%; half comes from just 1 funder.

the vertical line marks half of all grant income — 1 funder to its left

100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund DRUG INFORMATION ASSOCIATION INC.

77%
largest funder
100%
top three
~2
effective funders

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

77% of DRUG INFORMATION ASSOCIATION INC's grant income comes from Washington, D.C. funders.

MD
DC

Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

04Its place in the field

Against its field

DRUG INFORMATION ASSOCIATION INC's revenue fell 20% between 2017 and 2025.

Operating margin−15% · bottom quartile
Months of reserve0.6mo · below the median
Revenue growth (annualized)−3% · bottom quartile

this organization peer median middle 50% of peers· 2,969 health nonprofits $10M–$100M, FY2025

Government funding DRUG INFORMATION ASSOCIATION INC receives

Grants and contracts to this organization from federal (USASpending) and state checkbooks, reconciled to its EIN. $181k on record.

Federal$181k
grants $0contracts $181k
19
20
26
Top agencies
  • Department of Health and Human Services$181k

Federal grants vs contracts are distinguished; state line items keep their reported category. Matched by name + geography (the BMF), so coverage is partial and precision-first.

Organizations like DRUG INFORMATION ASSOCIATION INC

Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.

In Washington, D.C.

Nationally

05Profile & governance

Read directly from this organization’s own Form 990, as neutral context.

Where the money goes

74% of spending goes to programs.

Program 74%Management 26%Fundraising 0%

Governance

13
board members
92%
independent
✓Conflict-of-interest policy✓Whistleblower policy✓Document retention✓Board reviewed the 990✓Audited financials

Public support

95%

Share of support from the public (Schedule A) — the basis for its public-charity status.

Footprint & structure

Part of a family of 10 related entities

  • Drug Information Association LLC · disregarded
  • Dia Global Healthcare LLC · disregarded
  • Dia Learning LLC · disregarded
  • Dia Europe Gmbh · corp_trust
  • Dia E-Learning Europe Gmbh · corp_trust

Screen this organization

A dated, signed PDF of the compliance screen for DRUG INFORMATION ASSOCIATION INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.

A paid feature, included from the $75 plan up. Sign in to download.

Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf

Questions and answers

Who funds DRUG INFORMATION ASSOCIATION INC?
DRUG INFORMATION ASSOCIATION INC (Washington, D.C.) receives grants from 2 organizations whose IRS filings report $26,335 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($20,335). 0 of them have funded it in more than one year.
How many funders does DRUG INFORMATION ASSOCIATION INC have?
IRS filings report 2 organizations giving $26,335 in grants to DRUG INFORMATION ASSOCIATION INC.
Who is the largest funder of DRUG INFORMATION ASSOCIATION INC?
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA is the largest funder on record, with $20,335 in grants. The full list of funders is on this page.
How can an organization like DRUG INFORMATION ASSOCIATION INC find more funders?
Start with the funders already giving here, then look at the foundations that back similar organizations in Washington, D.C.. The funding by cause and by state pages list the largest funders for a given area and how to approach them.

These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 2 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing